Jupiter Neurosciences (JUNS) Total Current Liabilities (2023 - 2025)
Jupiter Neurosciences (JUNS) posted quarterly Total Current Liabilities of $7.4 million for Q4 2025, up 268.11% year-over-year from $2.0 million in Q4 2024, and up 193.62% quarter-over-quarter from $2.5 million in Q3 2025.
Jupiter Neurosciences (JUNS) Total Current Liabilities (2023 - 2025) Analysis & Trends
Jupiter Neurosciences (JUNS) has reported Total Current Liabilities for 3 consecutive years, with $7.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Current Liabilities rose 268.11% year-over-year to $7.4 million; the TTM figure through Dec 2025 stood at $7.4 million (up 268.11% YoY), while the FY2025 annual figure was $7.4 million, up 268.11% from the prior year.
- Total Current Liabilities climbed to $7.4 million in Q4 2025 per JUNS's latest filing, from $2.5 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $7.4 million in Q4 2025 and bottomed at $1.9 million in Q1 2025.
- Historically, Total Current Liabilities has averaged $4.0 million across 3 years, with a median of $2.6 million in 2025.
- Annual changes were most pronounced in 2024 — Total Current Liabilities slumped 65.19% — and 2025, when it surged 268.11%.
- Jupiter Neurosciences' Total Current Liabilities stood at $5.8 million in 2023, then plunged by 65.19% to $2.0 million in 2024, then soared by 268.11% to $7.4 million in 2025.
- Business Quant data shows JUNS's Total Current Liabilities at $7.4 million in Q4 2025, $2.5 million in Q3 2025, and $2.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Jupiter Neurosciences | 3.37 Mn | 1.85 Mn | 21,064.00 | 3.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.40 Mn |
| Sep 30, 2025 | 2.52 Mn |
| Jun 30, 2025 | 2.63 Mn |
| Mar 31, 2025 | 1.89 Mn |
| Dec 31, 2024 | 2.01 Mn |
| Sep 30, 2024 | 5.68 Mn |
| Dec 31, 2023 | 5.77 Mn |